All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoid malignancies that rank seventh in the causes of cancer-related deaths worldwide, with higher incidence in developed countries \[[@pone.0140819.ref001]\]. The annual incidence rate of NHL in the Czech Republic is approximately 12 per 100 000 inhabitants \[[@pone.0140819.ref002]\]. The majority of NHL cases arise sporadically, but various observations (familial clustering, and increased risk of NHL in monozygotic twins or other relatives of patients diagnosed with hematological malignancy) indicate that NHL development is affected by genetic factors that are only partially understood \[[@pone.0140819.ref003]--[@pone.0140819.ref006]\].

The checkpoint kinase 2 (*CHEK2*) gene (OMIM 604373) coding for CHK2 protein has been reported as a moderate-penetrance, multi-organ cancer susceptibility gene whose alterations increase the risk of different malignancies including breast, colorectal or prostate cancers \[[@pone.0140819.ref007]\]. CHK2 is a nuclear serine/threonine kinase contributing to the ATM-CHK2-p53 cascade, a part of the DNA damage response (DDR) system. Human CHK2 consists of three distinct functional domains, a N-terminal SQ/TQ cluster domain (SCD), a forkhead-associated domain (FHA), and a C-terminal Ser/Thr kinase domain (reviewed in \[[@pone.0140819.ref008]\]; [Fig 1](#pone.0140819.g001){ref-type="fig"}). The CHK2 kinase is activated by ATM-mediated phosphorylation \[[@pone.0140819.ref009]\]. Activated CHK2 consequently phosphorylates several effector proteins involved in regulation of the cell cycle and apoptosis upon DDR. The DDR and DNA repair systems represent a critical anti-cancer barrier activated by various cancer-promoting stimuli in precancerous lesions \[[@pone.0140819.ref010]--[@pone.0140819.ref012]\]. An impairment of this barrier caused by somatic or inherited alterations in genes coding for proteins involved in DDR or DNA repair induces genomic instability, one of the hallmarks of cancer cells \[[@pone.0140819.ref013]\]. Frequent occurrence of chromosomal rearrangements in NHL suggests that DDR and DNA repair may be constitutively deficient in NHL patients \[[@pone.0140819.ref014]\]. Moreover, it has been reported that inter-individual variability in the DDR system could modify the efficacy of chemotherapy during the treatment of hematological malignancies \[[@pone.0140819.ref015]\]. The relevance of *CHEK2* alterations to NHL remains unclear; however, a known increased risk of lymphoid malignancies (including childhood NHL) in patients suffering from ataxia-telangiectasia (a rare inherited cancer-prone syndrome caused by germ-line mutations in the *ATM* gene coding an upstream CHK2 activator) implicates *CHEK2* as a gene in which hereditary alterations may modify the risk of NHL development \[[@pone.0140819.ref016], [@pone.0140819.ref017]\]. In this study, we performed a mutation analysis of the entire coding sequence of *CHEK2* to establish the influence of inherited *CHEK2* alterations on the risk and course of NHL.

![A schematic diagram showing individual coding exons and flanking intronic sequences affected by the identified *CHEK2* sequence variants.\
The most important structural/functional domains of CHK2 kinase are depicted by color bars \[SQ/TQ domain (amino acid (aa) 19--69) in blue, FHA domain (aa 112--175) in yellow, and kinase domain (aa 220--486) in violet\]. The left-hand side shows synonymous and intronic *CHEK2* variants (italicized) while the right-hand side shows CHK2 protein structure-altering variants (frame-shift and missense) that were described in the NHL patients group (in red), controls (green) or in both populations (in black).](pone.0140819.g001){#pone.0140819.g001}

Materials and Methods {#sec002}
=====================

Study populations {#sec003}
-----------------

Five hundred and twenty-six NHL patients treated with first-line therapy were enrolled in the study at the First Department of Medicine--Department of Hematology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague. The only enrollment criterion was a histologically confirmed diagnosis of NHL according to the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. The initial analysis was performed in a group of 340 unselected NHL patients enrolled between May 2000 and June 2008 ([Table 1](#pone.0140819.t001){ref-type="table"}). A validation group of 186 consecutive patients with DLBCL enrolled between July 2008 and May 2011 ([Table 1](#pone.0140819.t001){ref-type="table"}) was used for an independent analysis of the c.319+43dupA variant that influenced the NHL prognosis in analysis of DLBCL subgroup from 340 unselected NHL patients. All clinical data were retrieved from the register of the Czech Lymphoma Study Group ([www.lymphoma.cz](http://www.lymphoma.cz/)) and from the patients' medical records. The control population consisted of 445 randomly selected non-cancer individuals. The inclusion criteria and characteristics of the control group consisting of 445 randomly selected non-cancer individuals were described previously \[[@pone.0140819.ref018]\]. All patients and controls were of Caucasian origin from the same geographical area. All participating subjects signed informed consent with genetic testing approved by the local ethics committee of the General University Hospital in Prague no. 23/07.

10.1371/journal.pone.0140819.t001

###### Clinical characteristics of NHL patients (N = 340) and DLBCL patients from the validation group (N = 186).

![](pone.0140819.t001){#pone.0140819.t001g}

  Histological subtype                            DLBCL              FL                 MCL                MALT               B SLL              Other              All NHLcases       Validation DLBCL
  ----------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  **Patients**; N(% of all NHL)                   180 (52.9)         71 (20.9)          19 (5.6)           16 (4.7)           11 (3.2)           43 (13.5)          340(100.0)         186
  **Age at diagnosis**; median of years (range)   58.7(20.9--83.4)   57.3(28.4--79.4)   63.1(46.6--81.9)   69.9(46.1--84.3)   65.8(47.8--84.5)   58.7(17.4--86.4)   59.6(17.4--86.4)   65.0(20.1--97.3)
  **Male**; N(%)                                  101 (56.1)         36 (50.7)          14 (73.7)          7 (43.8)           8 (72.7)           21 (48.8)          187 (55.0)         92 (49.5)
  **Female**; N(%)                                79 (43.9)          35 (49.3)          5 (26.3)           9 (56.2)           3 (27.3)           22 (51.2)          153 (45.0)         94 (50.5)
  **Clinical stage**; N (%)                                                                                                                                                            
  I                                               45 (25.7)          7 (10.1)           0                  5 (31.3)           0                  6 (15.8)           63 (19.4)          33 (18.4)
  II                                              37 (21.1)          12 (17.4)          0                  2 (12.5)           0                  6 (15.8)           57 (17.5)          34 (19.2)
  III                                             22 (12.6)          16 (23.2)          2 (11.8)           2 (12.5)           0                  4 (10.5)           46 (14.2)          24 (13.6)
  IV                                              71 (40.6)          34 (49.3)          15 (88.2)          7 (43.8)           11 (100.0)         22 (57.9)          160 (47.1)         86 (48.6)
  Missing                                         5 (2.8)            2 (2.8)            2 (12.5)           0                  0                  5 (11.6)           14 (4.1)           9 (4.8)
  **IPI**; N (%)                                                                                                                                                                       
  Low                                             64 (36.6)          38 (55.9)          2 (11.8)           5 (31.3)           0                  13 (38.2)          122 (38.1)         41 (24.6)
  Low intermediate                                56 (32.0)          17 (25.0)          6 (35.3)           4 (25.0)           5 (50.0)           5 (14.7)           93 (29.1)          35 (21.0)
  High intermediate                               26 (14.9)          9 (13.2)           5 (29.4)           5 (31.3)           4 (40.0)           7 (20.6)           56 (17.5)          36 (21.6)
  High                                            29 (16.6)          4 (5.9)            4 (23.5)           2 (12.5)           1 (10.0)           9 (26.5)           49 (15.3)          55 (32.9)
  Missing                                         5 (2.8)            3 (4.2)            2 (10.5)           0                  1 (9.1)            9 (20.9)           20 (5.9)           19 (10.2)
  **FLIPI**; N (%)                                                                                                                                                                     
  Low                                             \-                 31 (46.3)          \-                 \-                 \-                 \-                 \-                 \-
  Intermediate                                    \-                 21 (31.3)          \-                 \-                 \-                 \-                 \-                 \-
  High                                            \-                 15 (22.4)          \-                 \-                 \-                 \-                 \-                 \-
  Missing                                         \-                 4 (5.6)            \-                 \-                 \-                 \-                 \-                 \-

*DLBCL*---diffuse large B-cell lymphoma; *FL*---follicular lymphoma; *MCL*---mantle cell lymphoma; *MALT*---mucosa-associated lymphoid tissue lymphoma; *B SLL*---small lymphocytic lymphoma; *IPI*---international prognostic index; *FLIPI*---follicular lymphoma prognostic index.

Mutation analysis of the *CHEK2* gene {#sec004}
-------------------------------------

Genomic DNA was extracted from the peripheral blood of patients and controls by standard procedures. All coding *CHEK2* exons with intron-exonic boundaries were PCR-amplified in 14 fragments. To overcome the presence of numerous pseudogenes, a nested PCR was performed for exons 10--14 as described previously \[[@pone.0140819.ref019], [@pone.0140819.ref020]\]. PCR-amplified fragments were analyzed by denaturing high-performance liquid chromatography (DHPLC; WAVE3500; Transgenomic). Primers, PCR and DHPLC conditions are listed in [S1 Table](#pone.0140819.s005){ref-type="supplementary-material"}. Samples with aberrant elution profiles on DHPLC were sequenced from independent amplifications (ABI 3130; Life Technologies). The frequencies of identified alterations were estimated in the control group by the same method.

Analysis of *CHEK2* intragenic rearrangements {#sec005}
---------------------------------------------

A multiplex ligation-dependent probe amplification (MLPA) kit (SALSA MLPA kit P190 CHEK2; MRC-Holland, [www.mrc-holland.com](http://www.mrc-holland.com/)) was used according to the manufacturer's instructions. The analysis of *CHEK2* 5395 bp deletion (c.909-2028_1095+330del5395; M304Lfs\*16) in MLPA-positive samples and controls was performed by a PCR-based method described previously \[[@pone.0140819.ref021], [@pone.0140819.ref022]\].

Analysis of variants affecting *CHEK2* pre-mRNA splicing {#sec006}
--------------------------------------------------------

In order to evaluate the influence of the identified variants affecting the conservative splicing site (at the start of intron 2 and 10, respectively) on mRNA splicing, peripheral lymphocyte-derived RNA was extracted in particular mutations carriers during their regular follow-up and was reverse transcribed into cDNA using SuperScript III reverse transcriptase (Life Technologies), as described previously \[[@pone.0140819.ref023]\]. The amplicons covering exons 1--3 (sized 473 bp) and exons 9--11 (sized 314 bp) were amplified using primers 5'-ATATCCAGCTCCTCTACCAGC and 5'-CTGCTTAGTGACAGTGCAATTTCAG, and 5'-CATGAAAACGGTATTATACACCGTGAC and 5'-CCACTGGTGATCTGATCCTTCAG, respectively, and sequenced using the same primers on ABI 3130 (Life Technologies).

Nomenclature of *CHEK2* alterations and in silico analyses {#sec007}
----------------------------------------------------------

The nomenclature of *CHEK2* alterations reflects the Human Genome Variation Society guidelines (<http://www.hgvs.org/mutnomen/>) using NCBI *CHEK2* Reference Sequences NG_008150.1 (gene) and NM_007194.3 (mRNA). The first coding exon of *CHEK2* was designated here as exon 1 in line with the convention maintained in relevant literature.

The biological significance of missense variants was evaluated using the freely available web-based program Align-GVGD \[[@pone.0140819.ref024]\], SIFT \[[@pone.0140819.ref025]\], PolyPhen \[[@pone.0140819.ref026]\] and MutationTaster \[[@pone.0140819.ref027]\]. The effects of intronic variants on splicing were evaluated using the Alamut (Interactive Biosoftware) application \[[@pone.0140819.ref028]\].

Statistical analyses {#sec008}
--------------------

The two-sided Fisher\'s exact test was used for the evaluation of the differences between frequencies of alterations in the analyzed groups and subgroups. Odds ratios (OR) were calculated from 2 x 2 contingency tables. Differences in the patients' clinical characteristics were tested by nonparametric Wilcoxon or the Kruskal-Wallis tests or Spearman rank correlation. A survival analysis was performed using the Kaplan-Meier method; the differences between survival curves were evaluated by Wilcoxon and Log-rank tests and the hazard ratio (HR) was calculated using the Cox proportional hazard model. Survival data were available for 330 NHL patients from the initial group and all 186 patients from the DLBCL validation group with a median follow-up of patients alive at the last contact at 7.94 and 2.77 years, respectively. Progression-free survival (PFS) was defined as an interval from the date of diagnosis to the date of progression, relapse or death from any cause or the last follow-up date after the first-line treatment. Overall survival (OS) was defined as an interval from the date of diagnosis to the date of death from any cause or the last follow-up date. All analyses were performed using Statistica *v*.9.0 (StatSoft) or NCSS *v*.2007 (NCSS).

Results {#sec009}
=======

Characterization of *CHEK2* alterations and their impact on the risk of NHL development {#sec010}
---------------------------------------------------------------------------------------

We performed a germline sequence analysis of all known protein-coding exons of the *CHEK2* gene in 340 NHL patients. We identified four different mutations resulting in frame-shift and introduction of premature stop codons (truncations) and nine different missense variants ([Fig 1](#pone.0140819.g001){ref-type="fig"} and [Table 2](#pone.0140819.t002){ref-type="table"}) in the patients' group (the genotype data of 340 analyzed NHL patients are available in [S5 Table](#pone.0140819.s009){ref-type="supplementary-material"}). The overall frequency of these alterations changing the amino acid sequence of the wt CHK2 protein was significantly higher in NHL patients (25/340; 7.4%) compared to controls (12/445, 2.7%; *P* = 0.003). Truncating variants were identified only in NHL patients (*P* = 0.02; [Table 2](#pone.0140819.t002){ref-type="table"}). Two of them, c.1100delC and 5395 del, lead directly to a frame-shift and premature termination of translation. The other two truncating alterations, c.444+1G\>T and c.1259+1G\>C, were located in consensus splice donor sites; their effect on *CHEK2* pre-mRNA splicing, resulting in frame shifts and premature termination of translation, was confirmed by sequencing of mRNA (resp. cDNA; [S1](#pone.0140819.s001){ref-type="supplementary-material"} and [S2](#pone.0140819.s002){ref-type="supplementary-material"} Figs). The MLPA analysis revealed only c.1100delC and 5395 del mutations ([S3 Fig](#pone.0140819.s003){ref-type="supplementary-material"}). The frequency of the most common missense variant c.470T\>C (p.I157T) did not differ significantly between NHL patients and controls ([Table 2](#pone.0140819.t002){ref-type="table"}). Analysis of c.470T\>C and another eight missense mutations (seven found in the NHL group and two in controls) by mutation impact prediction software was inconclusive as to likely functional consequences ([S2 Table](#pone.0140819.s006){ref-type="supplementary-material"}), with the exception of p.R181H and p.N446D being consistently classified as neutral polymorphisms. Besides the 13 different mutations affecting the CHK2 protein sequence ([Fig 1](#pone.0140819.g001){ref-type="fig"} and [Table 2](#pone.0140819.t002){ref-type="table"}), another 15 variants including silent mutations and variants located deeper in intronic sequences and untranslated (UTR) regions were found ([Fig 1](#pone.0140819.g001){ref-type="fig"} and [Table 3](#pone.0140819.t003){ref-type="table"}). The most frequent variant of *CHEK2* identified in our study was intronic polymorphism c.319+43dupA. Interestingly, its frequency was significantly lower in NHL patients compared with controls: 75/340 (22.1%) vs. 139/445 (31.2%), respectively (*P* = 0.005; [Table 3](#pone.0140819.t003){ref-type="table"}).

10.1371/journal.pone.0140819.t002

###### Germline alterations of the *CHEK2* gene changing the CHK2 protein structure identified in NHL patients and controls with their frequencies and related odds ratios (OR).

![](pone.0140819.t002){#pone.0140819.t002g}

  Part of gene                                  Alteration; Genomic (protein) change                          dbSNP rs number   NHL (N = 340);*N* (%)       Controls (N = 445);*N* (%)   OR (95% CI)          *P* value
  --------------------------------------------- ------------------------------------------------------------- ----------------- --------------------------- ---------------------------- -------------------- -----------
  **Truncating variants**                                                                                                                                                                                     
  i2                                            c.444+1G\>T (p.E149Kfs\*12)                                   rs121908698       1 (0.3)                     0                            \-                   \-
  i7-i9                                         c.909-2028_1095+330del5395 (p.M304Lfs\*16)                    \-                2 (0.6)                     0                            \-                   \-
  E10                                           c.1100delC (p.T367Mfs\*15)                                    \-                1 (0.3)                     0                            \-                   \-
  i10                                           c.1259+1G\>C (p.I366Pfs\*2)                                   rs121908707       1 (0.3)                     0                            \-                   \-
  *All truncating alterations*                  *5 (1*.*5)*                                                   *0*               *-*                         *0*.*02*                                          
  **Missense variants**                                                                                                                                                                                       
  E1                                            c.192G\>A (p.E64K)                                            rs141568342       0                           1 (0.2)                      \-                   \-
  E3                                            c.470T\>C (p.I157T)                                           rs17879961        14 (4.1)                    10 (2.2)                     1.87 (0.82--4.26)    0.15
  E3                                            c.538C\>T (p.R180C)                                           rs77130927        1 (0.3)                     1 (0.2)                      1.31 (0.08--21.03)   1.00
  E3                                            c.542G\>A (p.R181H)                                           rs121908701       1 (0.3)                     0                            \-                   \-
  E5                                            c.715G\>A (p.E239K)                                           rs121908702       1 (0.3)                     0                            \-                   \-
  E9                                            c.1067C\>T (p.S356L)[^a^](#t002fn001){ref-type="table-fn"}    rs121908703       1 (0.3)                     0                            \-                   \-
  E10                                           c.1201A\>G (p.T401A) [^a^](#t002fn001){ref-type="table-fn"}   rs121908704       1 (0.3)                     0                            \-                   \-
  E11                                           c.1336A\>G (p.N446D)                                          rs121908705       1 (0.3)                     0                            \-                   \-
  E12                                           c.1421G\>A (p.R474H) [^a^](#t002fn001){ref-type="table-fn"}   rs121908706       1 (0.3)                     0                            \-                   \-
  *All missense variants*                       *21 (6*.*2)*                                                  *12 (2*.*7)*      *2*.*38 (1*.*15--4*.*90)*   *0*.*02*                                          
  *All alterations affecting coding sequence*   *25* [^b^](#t002fn002){ref-type="table-fn"} *(7*.*4)*         *12 (2*.*7)*      *2*.*86 (1*.*42--5*.*79)*   *0*.*003*                                         

^a^ New alterations

^b^ Two alterations of the *CHEK2* coding sequence were identified in one patient (c.470T\>C and c.1259+1G\>C); *OR*--odds ratio; *CI*--confidence interval.

Note: The nomenclature of *CHEK2* alterations was based on NCBI *CHEK2* Reference Sequences NG_008150.1 (gene) and NM_007194.3 (mRNA).

10.1371/journal.pone.0140819.t003

###### Germline intronic and silent alterations in the *CHEK2* gene in NHL patients and controls with their frequencies and related odds ratios (OR).

![](pone.0140819.t003){#pone.0140819.t003g}

  Part of gene   Alteration                                                        dbSNPrs number   NHL (N = 340);*N* (%)   Controls (N = 445);*N* (%)   OR (95% CI)         *P* value
  -------------- ----------------------------------------------------------------- ---------------- ----------------------- ---------------------------- ------------------- -----------
  E1             c.252A\>G (p.E84E)                                                rs1805129        22 (6.5)                28 (6.3)                     1.03 (0.58--1.84)   1.00
  i1             c.319+43dupA (A/AA)[^b^](#t003fn002){ref-type="table-fn"}         rs17879991       67 (19.7)               131 (29.4)                   0.59 (0.42--0.82)   0.002
  i1             c.319+43dupA (AA/AA)[^b^](#t003fn002){ref-type="table-fn"}        rs17879991       8 (2.4)                 8 (1.8)                      1.32 (0.49--3.54)   0.62
  i1             c.319+43dupA (A/AA+AA/AA)[^b^](#t003fn002){ref-type="table-fn"}   rs17879991       75 (22.1)               139 (31.2)                   0.62 (0.45--0.86)   0.005
  i1             c.320-5T\>A                                                       rs121908700      1 (0.3)                 0                            \-                  \-
  i2             c.444+24C\>T                                                      rs121908699      1 (0.3)                 0                            \-                  \-
  i3             c.592+50A\>T                                                      rs17881298       0                       2 (0.5)                      \-                  \-
  i4             c.684-78\_-100dup23                                               rs17881244       23 (6.8)                27 (6.1)                     1.12 (0.63--2.00)   0.77
  E8             c.990G\>A (p.Q330Q)                                               rs9625537        0                       1 (0.2)                      \-                  \-
  i8             c.1008+71A\>G [^a^](#t003fn001){ref-type="table-fn"}              rs121908713      1 (0.3)                 0                            \-                  \-
  i9             c.1095+19G\>A                                                     rs200020484      0                       2 (0.5)                      \-                  \-
  i9             c.1095+99A\>C                                                     \-               0                       1 (0.2)                      \-                  \-
  i9             c.1096-18T\>C                                                     \-               0                       1 (0.2)                      \-                  \-
  i10            c.1259+28A\>G [^a^](#t003fn001){ref-type="table-fn"}              rs121908708      1 (0.3)                 0                            \-                  \-
  i11            c.1375+16G\>A                                                     \-               0                       1 (0.2)                      \-                  \-
  i13            c.1543-31delT [^a^](#t003fn001){ref-type="table-fn"}              rs121908709      1 (0.3)                 0                            \-                  \-
  3'UTR          c.\*7T\>C [^a^](#t003fn001){ref-type="table-fn"}                  rs121908710      1 (0.3)                 0                            \-                  \-

^a^ New alterations

^b^The c.319+43dupA alteration also did not show a statistically significant deviation from the Hardy-Weinberg equilibrium in any of the analyzed groups (all p \> 0.05).

Because germline alterations affecting CHK2 protein sequence were found more frequently in NHL patients, they were associated with an increased risk of NHL development (OR = 2.86; 95% CI 1.42--5.79; [Table 2](#pone.0140819.t002){ref-type="table"}). These alterations were scattered among various types of NHL; as a result, despite relatively small numbers of patients for each type, their association with NHL was significant for follicular lymphoma (FL; *P* = 0.03), mantle cell lymphoma (MCL; *P* = 0.02), and B-small lymphocytic lymphoma (B-SLL; *P* = 0.004), and borderline for diffuse large B-cell lymphoma (DLBCL; *P* = 0.06; [S3 Table](#pone.0140819.s007){ref-type="supplementary-material"}). After excluding the most frequent missense variant I157T, the remaining relatively rare non-I157T CHK2 protein-modifying alterations were still significantly associated with an increased NHL risk (OR = 8.10; 95% CI 1.80--36.47; *P =* 0.002).

Interestingly, the carriers of at least one allele of the most frequent intronic variant c.319+43dupA were at a significantly lower risk of NHL development (OR = 0.62; 95% CI 0.45--0.86, *P* = 0.005). The protective effect of c.319+43dupA was also of borderline statistical significance in the two major types of NHL: DLBCL and FL (both *P =* 0.05; [S3 Table](#pone.0140819.s007){ref-type="supplementary-material"}).

Correlation of *CHEK2* alterations with survival of NHL patients {#sec011}
----------------------------------------------------------------

All identified *CHEK2* alterations were evaluated as potential prognostic factors modifying the survival of NHL patients. We found that CHK2 protein-modifying alterations were associated with worse progression-free survival (PFS) of NHL patients overall (i.e., regardless of histology type; HR~PFS~ = 2.1; P = 0.02; [Fig 2A](#pone.0140819.g002){ref-type="fig"}), and that the association was even stronger for carriers of the missense variant I157T compared with any other genotype (i.e. I157T vs. mutation-free or any other alteration; HR~PFS~ = 3.7 *P* = 0.007; [Fig 2B](#pone.0140819.g002){ref-type="fig"}). Similar but statistically insignificant results were observed for overall survival (OS, [Fig 2A and 2B](#pone.0140819.g002){ref-type="fig"}).

![Overall survival (OS; upper panels) and progression-free survival (PFS; lower panels) in all NHL patients (regardless of histology subtype) classified according to the type of *CHEK2* alterations.\
Panels show: **A.** the influence of all alterations affecting the CHK2 coding sequence (cds; HR~OS~ = 1.6; 95% CI 0.79--3.24 and HR~PFS~ = 2.1; 95% CI 1.12--4.05); **B.** the influence of the I157T mutation (HR~OS~ = 1.5; 95% CI 0.62--3.70 and HR~PFS~ = 3.7; 95% CI 1.42--9.43) and **C.** the influence of the c.319+43dupA variant (HR~OS~ = 0.8; 95% CI 0.50--1.15 and HR~PFS~ = 0.6; 95% CI 0.44--0.89).](pone.0140819.g002){#pone.0140819.g002}

We subsequently focused on 180 DLBCL patients, representing the most common type of NHL. The I157T mutation negatively affected PFS also in the DLBCL subgroup (HR~PFS~ = 5.2; *P* = 0.02; [Fig 3B](#pone.0140819.g003){ref-type="fig"}), but not significantly the OS. There was no statistically significant difference in survival between DLBCL patients with or without any germline mutation affecting CHK2 protein sequence ([Fig 3A](#pone.0140819.g003){ref-type="fig"}). The I157T mutation was also associated with a higher number of lymph node areas affected by the tumor in DLBCL patients (risk of more than four areas OR = 9.7; 95% CI 1.8--52.2; *P =* 0.008).

![Overall survival (OS; upper panels) and progression-free survival (PFS; lower panels) in DLBCL patients.\
Panels show: **A.** the influence of all alterations affecting the CHK2 coding sequence (cds; HR~OS~ = 2.3; 95% CI 0.77--6.97 and HR~PFS~ = 2.6; 95% CI 0.91--7.44); **B.** the influence of the I157T mutation (HR~OS~ = 2.9; 95% CI 0.70--12.00 and HR~PFS~ = 5.2; 95% CI 1.25--22.16) and **C.** the influence of the c.319+43dupA variant (HR~OS~ = 0.6; 95% CI 0.32--0.97 and HR~PFS~ = 0.5; 95% CI 0.32--0.86).](pone.0140819.g003){#pone.0140819.g003}

In contrast to CHK2 protein-modifying mutations, the most frequent *CHEK2* alteration c.319+43dupA (carried by 22% of NHL patients and associated with a decreased risk of NHL development) was significantly associated with better OS and PFS in DLBCL patients: HR~OS~ = 0.6 (*P* = 0.04) and HR~PFS~ = 0.5 (*P* = 0.01; [Fig 3C](#pone.0140819.g003){ref-type="fig"}). The association of c.319+43dupA with better PFS was also significant for the entire group of NHL patients, but c.319+43dupA did not modify OS in this group ([Fig 2C](#pone.0140819.g002){ref-type="fig"}). The c.319+43dupA alteration did not modify OS or PFS in any other NHL types (all *P* values were higher than 0.05) or in all NHL patients excluding DLBCL (HR~OS~ = 1.85; *P* = 0.1; HR~PFS~ = 0.97; *P* = 0.6). Therefore, its impact was limited to the DLBCL subgroup only. The c.319+43dupA alteration was also an independent positive prognostic factor for the DLBCL OS even when the International Prognostic Index (IPI) was included in the analysis: HR~OS,DupA~ = 0.38 (95% CI 0.16--0.94; *P* = 0.04) and high/intermediate high IPI HR~OS~ = 3.57 (95% CI 2.03--6.28; *P*\<0.0001). DLBCL carriers of the c.319+43dupA tended to be younger at NHL diagnosis: the median age at diagnosis of c.319+43dupA carriers (heterozygotes + homozygotes together) vs. all NHL patients without this alteration was 54.5 vs. 59.6 years, respectively (*P* = 0.02). The carriers of at least one allele with the c.319+43dupA alteration had also higher probability of bone marrow negativity (OR = 2.1; 95% CI 1.2--3.9; *P* = 0.02). Both these clinical factors could contribute to better survival of DLBCL patients. The type of therapy was essentially identical between carriers and non-carriers of c.319+43dupA. The majority of DLBCL patients were treated by chemotherapy classifiable as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone; [S4 Table](#pone.0140819.s008){ref-type="supplementary-material"}), but the protective effect of c.319+43dupA was the strongest and limited to patients treated by conventional chemotherapy only (HR~OS~ = 0.4; P = 0.03; HR~PFS~ = 0.4; P = 0.006), while the presence of c.319+43dupA did not modify survival in the DLBCL subgroup treated by rituximab-based chemoimmunotherapy ([S4A and S4B Fig](#pone.0140819.s008){ref-type="supplementary-material"}). Analysis of the additional 186 DLBCL patients (validation DLBCL group, [Table 1](#pone.0140819.t001){ref-type="table"}), where 95% patients were treated by rituximab ([S4 Table](#pone.0140819.s008){ref-type="supplementary-material"}), confirmed that c.319+43dupA do not affect survival of rituximab treated patients ([S4C Fig](#pone.0140819.s004){ref-type="supplementary-material"}). Analysis of CHEK2 mRNA (resp. cDNA) from the carriers of c.319+43dupA (homozygotes or heterozygotes) did not show any aberration of CHEK2 pre-mRNA slicing (data not shown); hence, the biological importance of this variant remains elusive.

We did not find any other correlation of a particular *CHEK2* alteration or group of alterations with other evaluated clinical characteristics (age, gender, clinical stage, IPI, FLIPI, bone marrow involvement, elevated LDH, number of lymph nodes areas affected by the tumor, extranodal involvement, maximum tumor diameter, and best response to treatment).

Discussion {#sec012}
==========

Non-Hodgkin lymphomas occur only rarely in an apparently familial form (OMIM 605027), and therefore it is unlikely that a strong, clinically meaningful high-penetrant NHL-susceptibility gene will be found. On the other hand, the influence of various low and/or medium-penetrant alleles on the risk of NHL has been documented \[[@pone.0140819.ref006]\]. A recent report describes germline polymorphisms in the LUBAC subunit RNF31, rare among healthy individuals (∼1%) but enriched in the ABC subtype of DLBCL (7.8%), that were shown by in vitro studies as likely contributory to the disease and providing a therapeutic target \[[@pone.0140819.ref029]\].

Germline alterations of the *CHEK2* gene were associated with a higher risk of several solid tumor types, but their association with hematological malignances was inconsistent or limited \[[@pone.0140819.ref007], [@pone.0140819.ref030]\]. We analyzed hereditary *CHEK2* variants in the entire coding sequence of the *CHEK2* gene in large group of NHL patients, and found that *CHEK2* variants could modify the risk and clinical course of NHL. Specifically, 7.4% of NHL patients are carriers of alterations affecting the CHK2 protein sequence, which are associated with an increased risk of NHL development (OR = 2.86; *P =* 0.003). Interestingly, this association was apparent also for major individual types of NHL, suggesting that the effect of CHK2 protein-modifying alterations is not limited to a particular type of NHL. Five out of 340 NHL patients (1.5%) carried a variant truncating the CHK2 protein sequence, in all cases upstream of the kinase domain, similarly to the 1100delC alteration (a well-known pathogenic mutation increasing the risk of various solid cancers). Therefore, a follow-up with specialized oncologists and genetic counseling for the families of these patients is highly recommended \[[@pone.0140819.ref031]\]. Two cases of large deletion (5395 del mutation), previously described as Slavic population-specific variant for its origin from Czech or Slovak regions \[[@pone.0140819.ref021]\], were found by a MLPA. Our results indicate that with the exception of 5395 del, large genomic rearrangements in the *CHEK2* gene are rare events. Other than this intragenic deletion, a 23 Kb duplication in a single Italian breast cancer patient is the only other known *CHEK2* rearrangement variant \[[@pone.0140819.ref032]\]. The presence of 5395 del in our NHL patients also indicates that this variant may not be associated only with breast \[[@pone.0140819.ref033]\] or prostate \[[@pone.0140819.ref034]\] cancer susceptibility. After the exclusion of clearly pathogenic truncating variants and the most frequent missense mutation I157T (whose frequency was not significantly different between our NHL patients and controls), all other relatively rare *CHEK2* missense variants occurred more frequently in the patients' group ([Fig 1](#pone.0140819.g001){ref-type="fig"}) and were also associated with an increased NHL risk (OR = 4.66; *P =* 0.045). A similar effect of such rare *CHEK2* variants has been reported for colorectal \[[@pone.0140819.ref022]\] and breast cancer \[[@pone.0140819.ref018], [@pone.0140819.ref035]\], supporting the importance of less frequent alterations in not-commonly analyzed *CHEK2* regions.

Our results are in accordance with the study by Cybulski, *et al* (2005), who analyzed tree founder *CHEK2* variants, p.I157T, IVS2+1G\>A (c.444+1G\>A) and c.1100delC, in a large population of cancer patients with various tumor types that included also a subgroup of 120 NHL cases \[[@pone.0140819.ref007]\]. In this subset, the I157T variant showed a borderline association with an increased risk of NHL development (OR 2.0; *P =* 0.05). In our study, the frequency of this variant was also higher in NHL cases compared with controls, but the difference was not statistically significant (4.1% vs. 2.2%, respectively; *P* = 0.15). The overall frequency of I157T was, however, considerably higher in the Polish compared with the Czech population (9.2% vs. 4.8%, respectively). Besides our work and the Cybulski report \[[@pone.0140819.ref007]\], all other studies on NHL patients analyzed primarily somatic *CHEK2* mutations \[[@pone.0140819.ref036]--[@pone.0140819.ref038]\]. A study by \[[@pone.0140819.ref039]\] is of particular interest because it describes *CHEK2* and other DNA repair genes being selectively somatically mutated in DLBCL tumors and thus supports the importance of the DDR system in NHL development. From a wider perspective, NHL might not be the only hematological malignancy associated with *CHEK2* germline alterations. We have recently reported an association of alterations localized within the *CHEK2* FHA domain coding region with an increased risk of Hodgkin lymphoma (OR = 2.11; *P =* 0.04; \[[@pone.0140819.ref040]\]. Further, *CHEK2* mutations (together with other genes implicated in DNA repair) were described as part of mutational landscape of T-cell prolymphocytic leukemia \[[@pone.0140819.ref041]\]. Janiszewska et al. suggested the contribution of four selected germline mutations (I157T, 1100delC, IVS2+1G\>A (c.444+1G\>A) and del5395) to the development of essential thrombocythemia (OR = 3.8; *P =* 0.002) \[[@pone.0140819.ref042]\]. Recently, they also identified an increased risk of polycythaemia vera (OR = 3.0; *P* = 0.004) in carriers of aforementioned *CHEK2* variants in Polish population \[[@pone.0140819.ref043]\]. A strong association was also reported for the *CHEK2* I157T mutation and an increased risk of chronic lymphocytic leukemia (OR = 14.83; *P =* 0.0008) \[[@pone.0140819.ref030]\].

Beyond NHL risk, alterations in the *CHEK2* gene have not been evaluated as a factor modifying NHL survival previously. We found germline mutations altering CHK2 protein sequence to be associated not only with an increased risk of NHL development, but also with unfavorable NHL survival in mutation carriers (NHL HR~PFS~ = 2.1; *P* = 0.02, [Fig 2A](#pone.0140819.g002){ref-type="fig"}). A similar pattern was also observed for the most frequent missense variant I157T alone and for CHK2 protein-modifying alterations in the most common NHL type, DLBCL (Figs [2B](#pone.0140819.g002){ref-type="fig"}, [3A and 3B](#pone.0140819.g003){ref-type="fig"}). *CHEK2* mutations have previously been linked to chemotherapy resistance: Chrisanthar et al. \[[@pone.0140819.ref044]\] reported an association of *CHEK2* mutations with resistance to anthracycline (doxorubicin and epirubicin) therapy in primary breast cancer and shown that decreased downstream p53 activation may contribute to anthracycline resistance in cancers with somatic deletion of wt *CHEK2* allele (loss of heterozygosity; LOH). A similar effect might be responsible for inferior PFS in NHL, for which doxorubicin is an essential part of most chemotherapy regimens; however, this hypothesis needs to be further investigated by LOH analyses in NHL tumor specimens of *CHEK2* hereditary mutation carriers (not available in our study) and especially by *in vivo* models. Changes in CHK2 function could also affect the efficacy of other agents used for NHL treatment (e.g., cyclophosphamide), since CHK2 is a member of a pathway executing response to DNA-damaging agents in general \[[@pone.0140819.ref045]\].

The c.319+43dupA alteration was the only variant significantly associated with a decreased risk of NHL (OR = 0.62; *P* = 0.005). Interestingly, our analysis suggested that c.319+43dupA might be also an independent positive prognostic factor associated with better OS and PFS of DLBCL, but the protective effect of c.319+43dupA on survival was limited to patients treated by conventional chemotherapy only (without rituximab; [S4 Fig](#pone.0140819.s004){ref-type="supplementary-material"}). It indicates that adding rituximab to the therapeutic regimen might overcome chemotherapy-resistance highlighted by the absence of c.319+43dupA alteration, and that the carriers of this alteration may respond to conventional chemotherapy well even without rituximab. Similar effect of rituximab was reported for negative prognostic impact of cyclin E expression in DLBCL \[[@pone.0140819.ref046]\]. Longer follow-up and/or a larger group of patients might be needed to detect eventual differences in survival associated with the c.319+43dupA polymorphism in the era of rituximab that substantially improved the overall survival rates. The mechanistic and biological rationale of how the *CHEK2* c.319+43dupA allele may modify the CHK2 function is unclear. Computer predictions and analysis of mRNA did not reveal interaction of this variant with *CHEK2* pre-mRNA splicing (data not shown). However, other processes influencing gene transcription (at the level of intronic splicing enhancers/silencers) or mRNA metabolism (RNA interference, stability or processing) may be involved. Moreover, the effect of another locus in linkage with c.319+43dupA cannot be ruled out.

In conclusion, our results indicate that relatively frequent germline *CHEK2* mutations (present in 7.4% of NHL patients) are associated with a moderately increased risk of NHL and unfavorable prognosis. However, further independent studies in NHL patients are required to confirm this association and the biological consequences of *CHEK2* mutations in the development of NHL. We have also shown that germline mutations of the *CHEK2* gene are not restricted to the previously analyzed regions (FHA and kinase domains) but are scattered across the entire coding sequence, and that intragenic rearrangements in the *CHEK2* gene are rare events with only two Slavic founder mutations (5395 del) and no other types detected in our analysis. The c.319+43dupA polymorphism was associated with a decreased risk of NHL development; however, the role of c.319+43dupA as an independent marker of positive prognosis in DLBCL needs further investigations.

Supporting Information {#sec013}
======================

###### Identification of the c.444+1G\>T variant.

The *CHEK2* mutation c.444+1G\>T (MUT) as it appeared in a DHPLC analysis (A) performed at 56.5°C. Sequencing chromatograms showing the sequence of this variant amplified form gDNA (B) and RNA (resp. cDNA; C). G-to-T transversion affecting the first nucleotide in the intron 2 (low letters) results in a selection of the aberrant splicing "gt" dinucleotide (underlined in B) that results in the formation of mutant mRNA containing a deleted last guanosine from exon 2 (depicted in C) which leads to the frame-shift and premature termination of translation (p.E149Kfs\*12). The lower signal of the mutant c.444+1G\>T allele (C) compared with the wild type (WT) allele signal in amplicons from cDNA synthesized from the peripheral blood leucocytes' total RNA of the c.444+1G\>T mutation carrier may be the result of the nonsense-mediated decay activity depredating mutation-bearing mRNA that contains the premature termination codon.

(TIF)

###### 

Click here for additional data file.

###### Identification of the c.1259+1G\>C variant.

The *CHEK2* mutation c.1259+1G\>C (MUT) as it appeared in DHPLC analysis (A) performed at 56.2°C. Sequencing chromatograms showing the sequence of this variant amplified form gDNA (B) and RNA (resp. cDNA; C, showing the borders of aberrant splicing product sequenced with forward (left) and reverse (right) sequencing primers). G-to-C transversion affecting the first nucleotide in the intron 10 (low letters) results in the cessation of the intron 10 donor splice site. This causes aberrant splicing with exon 10 skipping (C) that results in the frame-shift and premature termination of translation (p.I336Pfs\*2).

(TIF)

###### 

Click here for additional data file.

###### Identification of LGR using MLPA.

Results of the MLPA analysis using the Coffalyser software showing a sample with a wild-type *CHEK2* sequence (A) and a sample carrying a large 5395 bp deletion (B) affecting the exons 8 and 9 (denominated in MLPA as exons 9 and 10, red bars).

(TIF)

###### 

Click here for additional data file.

###### Kaplan-Meier estimates of overall survival (OS; upper panels) and progression-free survival (PFS, lower panels) in patients from the originally tested DLBCL subgroup (A and B) and the DLBCL validation group (C) classified according to the presence of the c.319+43dupA variant.

Panels show the OS and PFS in: A. patients treated only by conventional chemotherapy (HR~OS~ = 0.4; 95% CI 0.18--0.91; HR~PFS~ = 0.4; 95% CI 0.17--0.74), B. patients treated by rituximab-based chemoimmunotherapy (RTX; HR~OS~ = 0.8; 95% CI 0.36--1.17; HR~PFS~ = 0.7; 95% CI 0.36--1.50), and C. all patients from the DLBCL validation group (95% of patients treated with rituximab-based regimen; HR~OS~ = 0.8; 95% CI 0.40--1.39; HR~PFS~ = 0.8; 95% CI 0.47--1.40).

(TIF)

###### 

Click here for additional data file.

###### Conditions for PCR amplification of *CHEK2* coding sequence and following DHPLC analysis.

(PDF)

###### 

Click here for additional data file.

###### Predicted effects of the *CHEK2* missense variants identified in NHL patients in this study using software prediction.

(PDF)

###### 

Click here for additional data file.

###### Risk of NHL subtypes development in carriers of mutations modifying CHK2 protein structure and c.319+43dupA variant.

(PDF)

###### 

Click here for additional data file.

###### Comparison of therapy type between c.319+43dupA carriers and non-carriers (original group of DLBCL patients) and between two analyzed DLBCL groups.

(PDF)

###### 

Click here for additional data file.

###### Results of mutational analysis in 340 NHL patients showing individual CHEK2 genotypes.

(XLSX)

###### 

Click here for additional data file.
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